Last reviewed · How we verify

NCT05510583: TELESUR-GDM

MyDiabby Healthcare Vs Diary in Gestational Diabetes Mellitus.

Completed Last updated 19 September 2024
What this trial tests

trial testing Control group in Gestational Diabetes in 668 participants. Completed in 17 April 2023.

Timeline
2 August 2022
Primary endpoint
17 April 2023
17 April 2023

Quick facts

Lead sponsorHôpital NOVO
StatusCompleted
Study typeOBSERVATIONAL
Enrollment668
Start date2 August 2022
Primary completion17 April 2023
Estimated completion17 April 2023
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

Hôpital NOVO — full company profile →

Who can join

18 and older, female only, with Gestational Diabetes. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of the study is to demonstrate the non-inferiority of the onset of maternal, foetal, and neonatal complications for patients who had Gestational diabetes mellitus (GDM) and who had been monitored by myDiabby Healthcare compared to patients who had a classic glycemic blood monitoring by diary

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Control group

Trials testing the same drug.

Other recruiting trials for Gestational Diabetes

Currently open trials in the same condition.

Other Hôpital NOVO trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05510583.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing